DrugPatentWatch - Biopharmaceutical Business Intelligence
Profile for Gilead Sciences, Inc. (GILD)
« Back to company indexGILD Chatter Timeline
Stock Ticker for GILD
Most Active Tweeters for GILD
| User | Tweets |
|---|---|
| @thefinreviewer | 37 |
| @sesiegler | 12 |
| @WatchlistN | 10 |
| @macondailynews | 8 |
| @AmericanBanking | 7 |
Recent Tweets for GILD
 |
@WatchlistN $5.33 Billion in Sales Expected for Gilead Sciences, Inc. $GILD This Quarter https://t.co/AVBIRl1jQ6 12:02am |
 |
@WeekHerald Gilead Sciences, Inc. $GILD Expected to Post Quarterly Sales of $5.33 Billion https://t.co/3TQXkRqtrz February 21st 2019, 11:02pm |
 |
@ThisLincolnian Zacks: Brokerages Anticipate Gilead Sciences, Inc. $GILD Will Post Quarterly Sales of $5.33 Billion https://t.co/GkEIjklj6L February 21st 2019, 11:02pm |
 |
@PM_Flav RT @endpts: Off-the-shelf CAR-T from stem cells? An early look at UCLA tech — licensed by Gilead https://t.co/TbsxxezwMT $GILD February 21st 2019, 11:02pm |
 |
@endpts Off-the-shelf CAR-T from stem cells? An early look at UCLA tech — licensed by Gilead https://t.co/TbsxxezwMT $GILD February 21st 2019, 10:02pm |
 |
@ProVesting $ABBV $GILD: What Pharma Investors Need to Know About Pfizer’s Latest Disaster: https://t.co/0qCjD9lMeh February 21st 2019, 9:02pm |
 |
@Focus_on_Dvds Gilead’s (GILD) Dividend is Solid, But Growth Challenges Linger $GILD https://t.co/NpZogTYLMm #dividend #investing https://t.co/Vcqf7I6VhA February 21st 2019, 6:02pm |
 |
@schauwersb RT @BiotechRadar: $GLPG $GILD interesting wording for filgo filing... https://t.co/9BMhaHRxxD February 21st 2019, 5:02pm |
 |
@BiotechRadar $GLPG $GILD interesting wording for filgo filing... https://t.co/9BMhaHRxxD February 21st 2019, 5:02pm |
 |
@Bacosan1979 RT @bio_clouseau: $GLPG also says possible filing 2H19. FWIW here's the $GILD guidance for filgo so maybe GLPG jumping the gun a little bit… February 21st 2019, 4:02pm |
 |
@sesiegler RT @sesiegler: Well, this is really interesting. $BMY $GILD https://t.co/nxuVxtFXaT February 21st 2019, 4:02pm |
|
@sesiegler $GILD is trying to distract from the real story. https://t.co/2EkG8SCIrL February 21st 2019, 4:02pm |
|
@sesiegler How many times is $GILD going to try to use ATO for some positive publicity? Why don’t you ask about the #Yescarta… https://t.co/CLEn21YuN3 February 21st 2019, 4:02pm |
|
@sesiegler Oh, @endpts, this is not news. I even caught $GILD scrubbing the PR on this story, the 2019 version. https://t.co/vjU41z4dU7 February 21st 2019, 4:02pm |
 |
@bio_clouseau $GLPG also says possible filing 2H19. FWIW here's the $GILD guidance for filgo so maybe GLPG jumping the gun a litt… https://t.co/CQIpwePbJW February 21st 2019, 4:02pm |
 |
@_B_I_O_T_E_C_H_ On Call" Series: $ICPT, $GILD, #NASH Conf Call with Dr. Harrison Friday (2/22) at 9am ET / 6am PT, Michael Yee Con… https://t.co/SiEmNGeLcX February 21st 2019, 3:02pm |
|
@sesiegler Makes sense based off what we learned from @GruppSteve. #CARTcells $GILD https://t.co/fvNRsiETI7 February 21st 2019, 1:02pm |
 |
@Stock_News_Now $GILD: New SEC Filing for GILD: Form CT ORDER (No. 9999999997-19-000472): https://t.co/EB6DrbBilN February 21st 2019, 12:02pm |
 |
@Allstocknews $GILD New Form CT ORDER for Gilead Sciences From our Stock News Alerts App February 21st 2019, 11:02am |
 |
@confcalltran Confidential treatment order https://t.co/A9APpCqJlP $GILD February 21st 2019, 11:02am |
 |
@StockTexts $GILD Gilead Sciences, Inc. SEC Filing: Form CT ORDER https://t.co/exeVfDhJWV February 21st 2019, 11:02am |
 |
@alexserri1 $GILD - Confidential Treatment Order (ct Order) https://t.co/DvJE8gAHuE February 21st 2019, 11:02am |
|
@Bacosan1979 RT @BiotechRadar: $GLPG $GILD 2 phase IIa studies investigating filgotinib fully enrolled recently: in Lupus Membranous Nephropathy https:/… February 21st 2019, 11:02am |
|
@dakotafinancial Gilead Sciences, Inc. $GILD Director Gayle E. Wilson Sells 19,068 Shares of Stock https://t.co/YA5HVjzC3X February 21st 2019, 11:02am |
|
@BiotechRadar $GLPG $GILD 2 phase IIa studies investigating filgotinib fully enrolled recently: in Lupus Membranous Nephropathy… https://t.co/QTsdJEa7DF February 21st 2019, 11:02am |
 |
@macondailynews Gayle E. Wilson Sells 19,068 Shares of Gilead Sciences, Inc. $GILD Stock https://t.co/2tSDT75pzM February 21st 2019, 11:02am |
 |
@Backtested Long 1400 shares of $GILD at $66.18 for a swing trade. February 21st 2019, 10:02am |
 |
@whatsonthorold2 Gilead Sciences INC $GILD Holder Callahan Advisors LLC Decreased Its Holding https://t.co/RgRiIpyBdf February 21st 2019, 8:02am |
 |
@reurope_stock As Gilead Sciences INC $GILD Shares Declined, Callahan Advisors LLC Has Trimmed by $4.12 Million Its Position https://t.co/Or2jCixir5 February 21st 2019, 8:02am |
|
@Focus_on_Dvds Gilead’s (GILD) Dividend is Solid, But #Growth Challenges Linger $GILD https://t.co/NpZogTYLMm #dividend #investing https://t.co/vWRgJ4Papi February 21st 2019, 8:02am |
 |
@thefinreviewer American National Bank Has Boosted Gilead Sciences Com $GILD Stake By $689,535; CANNEX CAPITAL HOLDINGS ORDINARY S… https://t.co/btff1SxSRw February 21st 2019, 5:02am |
|
@Focus_on_Dvds Gilead’s (GILD) Dividend is Solid, But Growth Challenges Linger $GILD https://t.co/NpZogTYLMm #dividend #investing https://t.co/twSwAPvZT9 February 20th 2019, 9:02pm |
 |
@InsiderAlertsIA $GILD: New Insider Filing on Director GAYLE E WILSON: https://t.co/fVcqxGMW7Y February 20th 2019, 8:02pm |
|
@confcalltran Gilead Sciences director just cashed-in 19,068 options https://t.co/vWl8gUNgwh $GILD February 20th 2019, 8:02pm |
 |
@AmericanBanking Insider Selling: Gilead Sciences, Inc. $GILD Director Sells 19,068 Shares of Stock https://t.co/ClfGZWcmlI #stocks February 20th 2019, 8:02pm |
 |
@optioncharts $GILD open interest for maturity 02/22/2019. High put=66.00 High call=68.00 #maxpain #options… https://t.co/RhesvLewxU February 20th 2019, 8:02pm |
 |
@ZolmaxNews Insider Selling: Gilead Sciences, Inc. $GILD Director Sells 19,068 Shares of Stock https://t.co/P1gUi2dfnt February 20th 2019, 8:02pm |
|
@StockTexts $GILD Gilead Sciences, Inc. SEC Filing: Form 4 https://t.co/X3fpfI1ofX February 20th 2019, 8:02pm |
 |
@Lacktivist @Gabriel42869026 Yeah… but $ICPT reaction all about commercial prospects. VKTX was up when $GILD failed. One player… https://t.co/DaWGNsTSuE February 20th 2019, 8:02pm |
 |
@lblegend33 @Orangeman1992 @ihors3 $gild won’t make a move yet imho until stellar 3 comes out. Which is 2-3 months away February 20th 2019, 1:02pm |
 |
@Orangeman1992 @lblegend33 @ihors3 If $GILD is in the market, it is smiling today. It can pick up the pieces cheap. It is not BP.… https://t.co/zjvaCEUsQi February 20th 2019, 1:02pm |
|
@bio_clouseau @jq1234t @MauriceOnTW Thats true. Almost all oncology drugs do get PR so $GILD likely uses the solitary PRV for Fil… https://t.co/PkVfRDrJQC February 20th 2019, 12:02pm |
 |
@gmion11 $CELG $GILD CELG v GILD 2:17-cv-7639 updated - 2019-2-20 12:41:16 - ORDER RETURNING CASE FOR REASSIGNMENT UPON RECU… https://t.co/EbSvrXQ3i5 February 20th 2019, 12:02pm |
|
@Focus_on_Dvds Gilead’s (GILD) Dividend is Solid, But #Growth Challenges Linger $GILD https://t.co/NpZogTYLMm #dividend #investing https://t.co/u2uXQmflY0 February 20th 2019, 11:02am |
 |
@income_inv $GILD is a rare instance of a #biotech stock being a high-quality #dividend stock: https://t.co/WNBnzpRN3I February 20th 2019, 11:02am |
 |
@jq1234t @bio_clouseau @MauriceOnTW Why would anyone need to use PRV on CAR-T? CAR-T gets priority review anyway. $GILD had… https://t.co/sdwLgFYgFZ February 20th 2019, 10:02am |
|
@bio_clouseau @MauriceOnTW that table confirms only 1 $GILD PRV unaccounted for February 20th 2019, 10:02am |
|
@bio_clouseau @MauriceOnTW Many? I think it has only 1 left isnt it? Depends on whether $GILD wants to use it on maybe a CART BLA… https://t.co/zmwo1thScR February 20th 2019, 10:02am |
|
@whatsonthorold2 Gilead Sciences INC $GILD Market Valuation Declined While Natixis Raised Holding https://t.co/qe4rIgU48N February 20th 2019, 10:02am |
 |
@SwingTradeBot 50 DMA Resistance today: $TECK $GILD ... https://t.co/mnYaiRq1wk February 20th 2019, 9:02am |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2019. All rights reserved.